PD-1/PD-L1 Inhibitors Plus Antiangiogenic Drugs Versus Sorafenib as the First Line Treatment for Advanced Hepatocellular Carcinoma: A Phase 3 RCTs Based Meta-Analysis

• Published in: Technology in cancer research & treatment Vol. 23; p. 15330338241305700
• Main Authors: Li, Jun, Liao, Chun, Liu, Zhaohui, Xiong, Hu, Cai, Jing, Liu, Tiande
• Format: Journal Article
• Language: English
• Published: Los Angeles, CA SAGE Publications 01.01.2024; Sage Publications Ltd; SAGE Publishing
• Subjects: Angiogenesis Inhibitors - administration & dosage; Angiogenesis Inhibitors - adverse effects; Antiangiogenic agents; Antineoplastic Combined Chemotherapy Protocols - administration & dosage; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antitumor activity; B7-H1 Antigen - antagonists & inhibitors; Carcinoma, Hepatocellular - drug therapy; Carcinoma, Hepatocellular - mortality; Carcinoma, Hepatocellular - pathology; Clinical trials; Clinical Trials, Phase III as Topic; Combination Strategies and Personalized Therapeutic Strategies for Cancer Treatment; Disease control; Drug dosages; Evidence; Hepatocellular carcinoma; Humans; Immune Checkpoint Inhibitors - administration & dosage; Immune Checkpoint Inhibitors - adverse effects; Inhibitor drugs; Liver cancer; Liver Neoplasms - drug therapy; Liver Neoplasms - mortality; Liver Neoplasms - pathology; Neoplasm Staging; PD-1 protein; PD-L1 protein; Programmed Cell Death 1 Receptor - antagonists & inhibitors; Quality of Life; Randomized Controlled Trials as Topic; Sorafenib - administration & dosage; Sorafenib - adverse effects; Survival; Targeted cancer therapy; Treatment Outcome; antiangiogenic drugs; meta-analysis; PD-1/PD-L1 inhibitors; sorafenib; hepatocellular carcinoma

Background For advanced hepatocellular carcinoma (HCC), sorafenib remains the established therapy. PD-1/PD-L1 inhibitors plus antiangiogenic drugs (PIAD) as a new therapeutic approach for advanced HCC is still a subject of clinical debate regarding whether they offer improved treatment outcomes. Thi...